CG enters its Q1 2026 earnings call on May 7 with the stock up sharply on the week, a cluster of recent analyst target cuts, and insider selling that has run consistently since February — a setup where the price momentum and the fundamental narrative are pulling in different directions.
The most striking feature of recent weeks is the gap between the stock's trajectory and the Street's revised expectations. Carlyle closed at $51.29, up 7.5% on the week and 10.2% over the past month. But analysts have been cutting, not raising. Goldman Sachs trimmed its target to $69 from $81 on April 7, keeping a Buy but signalling reduced conviction. JP Morgan shaved a dollar off its Neutral target to $66 last week. Morgan Stanley also maintained Equal-Weight but pulled its target to $66 from $71 in mid-April. The lone mover in the other direction was Evercore ISI, which raised its In-Line target to $56 from $52 — still well below the consensus mean of $61.81, and closer to where the stock now trades. The direction of travel for most of the Street is lower targets with unchanged ratings: a cautious hold rather than a concerted exit, but the upside is compressing as the stock recovers.
Short interest tells a measured story. At roughly 1.7% of the free float, the short position is modest and has barely moved over the past five weeks. The week-on-week uptick of about 4.6% in estimated shares short brings the absolute figure to around 15.5 million shares — a rise in nominal terms, but still well within the range that has prevailed since late March. Borrow conditions are loose: cost to borrow is just 0.41%, down about 10% over the past month, and availability is running at more than 780% of short interest, meaning there is ample lending supply relative to existing shorts. The short score of 46.4 is unremarkable. None of this points to meaningful short-side conviction ahead of earnings.
Options positioning is similarly relaxed. The put/call ratio of 0.52 is only marginally above its 20-day average of 0.496 — a z-score of 0.35, well within normal bounds. For context, the 52-week high on that ratio sits at 2.30, so the current reading is far from any defensive extreme. Options traders are neither hedging aggressively nor positioning for a breakout; the market is approaching tomorrow's print with relative equanimity.
The ownership picture introduces some texture worth noting. Three of Carlyle's founders remain among the largest holders — Daniel D'Aniello at 9%, David Rubenstein at 7.6%, and William Conway at 7.5% — and collectively they represent a significant anchor on the float. Rubenstein sold 500,000 shares at $46.68 in mid-March, a $23.3 million disposal that came when the stock was trading below where it is now. CEO Harvey Schwartz sold 134,812 shares at $54.49 in February, as did a cluster of other C-suite names on the same day — Co-Presidents Nedelman and Jenkins, CFO Redett, and COO LoBue all reduced positions. The aggregate net selling over the 90-day window ending in March totalled nearly $85.6 million in value. The pattern is consistent with tax and compensation-driven activity after a post-results move, rather than a directional signal, but the volume is notable.
The forward EPS picture has some support. The 12-month forward EPS year-on-year increase ranks in the 85th percentile of the universe, a genuine positive. EPS momentum over the past 30 and 90 days is weaker — 13th and 21st percentile respectively — suggesting the forward estimates are firm but haven't been revised higher recently. The dividend score ranks in the 81st percentile, consistent with a yield of about 2.9% at current prices. Valuation is not stretched: the P/E has expanded about 1.2 turns over the past month to just over 11x, while price-to-book has moved to 1.44x. Most of the peer group — TPG, BX, KKR — also rallied strongly this week, with TPG up 7.4% and StepStone (STEP) up 6.4%, suggesting the move in CG reflects broad alternative-manager sentiment more than a Carlyle-specific catalyst.
Tomorrow's earnings call is therefore less about whether AUM growth is on track and more about whether Carlyle can articulate a credible path to monetisation and realisation activity in an environment where deal flow has been uneven — and whether management has anything to say about the pace of target compression from its own sell-side coverage.
See the live data behind this article on ORTEX.
Open CG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
